Merck’s $1B cash gamble pays off with a surprising PhIII cardio success for Bayer’s heart drug vericiguat
More than 3 years after Merck stepped up and paid $1 billion in cold, hard cash to gain the US commercial rights to Bayer’s high …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
